An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
BIL also holds an option to increase its equity stake by an additional 15%
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Subscribe To Our Newsletter & Stay Updated
